A retrospective, real-world study for dose-optimisation of lenvatinb for patients with unresectable hepatocellular carcinoma
Latest Information Update: 01 Mar 2021
Price :
$35 *
At a glance
- Drugs Lenvatinib (Primary)
- Indications Liver cancer
- Focus Adverse reactions; Therapeutic Use
- 01 Mar 2021 New trial record
- 17 Jan 2021 Results presented at the 2021 Gastrointestinal Cancers Symposium